Ratings LeMaitre Vascular, Inc. Börse Stuttgart

Equities

LHU

US5255582018

Market Closed - Börse Stuttgart Other stock markets 07:44:11 28/06/2024 pm IST			5-day change	1st Jan Change
76.5 ^EUR	+2.00%		+1.32%	+47.12%

03/06	Lemaitre Vascular, Inc. Announces Resignation of Lawrence J. Jasinski as A Director	CI
31/05	Roth MKM Upgrades LeMaitre Vascular to Buy Rating With $100 Price Target	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.43 times its estimated earnings per share for the ongoing year.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
LEMAITRE VASCULAR, INC.	+47.12%	1.85B	-
DANAHER CORPORATION	+8.00%	185B	B-
INTUITIVE SURGICAL, INC.	+31.86%	158B	B-
BOSTON SCIENTIFIC CORPORATION	+33.21%	113B	A-
SIEMENS HEALTHINEERS AG	+2.28%	64.32B	A-
EDWARDS LIFESCIENCES CORPORATION	+21.14%	55.66B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.11%	48.41B	B+
AGILENT TECHNOLOGIES, INC.	-6.76%	37.82B	A
GE HEALTHCARE TECHNOLOGIES INC.	+0.78%	35.57B	-
RESMED, INC.	+11.28%	28.12B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes